Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

NCT03212313 is registered in ClinicalTrials.gov with Biotie Therapies Inc. as lead sponsor.

NCT NCT03212313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03212313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant
Lead sponsor
Biotie Therapies Inc.
Phase
Phase 1
Overall status
Terminated
Start date
June 30, 2017
Completion date
December 31, 2017
Enrollment
20 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment